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Abstract 
Glaucoma is a multifactorial neurodegenerative disease associated with RGC loss. 
Increasing reports of similarities in glaucoma and other neurodegenerative conditions, 
have led to speculation that therapies for brain neurodegenerative disorders may also have 
potential as glaucoma therapies. Memantine is an NMDA antagonist approved for 
Alzheimer’s disease treatment. Glutamate-induced excitotoxicity is implicated in 
glaucoma and NMDA receptor antagonism has been advocated as a potential strategy for 
RGC preservation. This study describes the development of a topical formulation of 
memantine loaded PLGA-PEG nanoparticles (MEM-NP) and investigates the efficacy of 
this formulation using a well-established glaucoma model. Nanoparticles were 
characterized by dynamic light scattering and 1H-NMR, confirming the nanoparticle 
character (< 200nm) and high drug incorporation (4 mg/mL of which 0.35 mg/mL was 
localized within the aqueous interior). In vitro assessment indicates an element of 
sustained release and ex vivo corneal and scleral permeation studies demonstrate that 
incorporation into a nanoparticle enhanced memantine delivery. Moreover, MEM-NP 
was shown to be well-tolerated in human retinoblastoma cells and in vivo (Draize test). 
MEM-NP eye drops were applied daily for three weeks to a rodent model of ocular 
hypertension. MEM-NP were found to significantly (p<0.0001) reduce RGC loss. These 
results suggest that topical MEM-NP is safe, well-tolerated and most promisingly, 
neuroprotective in an experimental glaucoma model. 
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1. Introduction 
Glaucoma is a multifactorial neurodegenerative disease and the second leading cause of 
vision loss worldwide.[1] Although the exact mechanism of glaucoma pathology is 
debatable,[2,3] the disease induces damage to optic nerve axons thus resulting in 
progressive loss of retinal ganglion cells (RGC). Elevated intraocular pressure presently 
remains the only clinically modifiable risk factor for glaucoma and, therefore, traditional 
therapeutic strategies seek to reduce elevated intraocular pressure (IOP). However, there 
are patients who suffer glaucoma and vision loss with normotensive IOP values.[4] 
Although it has been shown that there is some improvement in the course of the disease 
in normotensive glaucoma (NTG) patients by lowering the IOP, there is growing 
recognition that IOP reduction alone is not adequate in some patients who continue to 
lose vision despite well-controlled IOPs.[4,5] As a result, there has been widespread 
research on IOP-independent neuroprotective strategies [6] for glaucoma patients.[7]  
Increasingly, there has been a recognition that similar mechanisms of cell death occur in 
glaucoma and Alzheimer’s disease (AD), including dysregulation of neurotrophic growth 
factors, caspase activation, and glutamate excitotoxicity.[8] Therapies advocated in AD 
have also been suggested for glaucoma. One such treatment is the NMDA (N-methyl-D-
aspartate) receptor antagonists Memantine (MEM).[9] 
 
MEM is a neuroprotective agent approved by the FDA for the treatment of AD that acts 
by inhibiting NMDA-induced glutamate excitotoxicity; it may also prevent RGC death 
in glaucoma.[5] Although preclinical data previously suggested a potential clinical benefit 
of orally administered MEM for the treatment of glaucoma,[10] the efficacy of this route 
of MEM administration is limited, and may have contributed to the results of a phase III 
clinical trial in glaucoma which apparently failed in meeting its primary endpoint.[11,12] 
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A key challenge for MEM in glaucoma is the development of a safe and effective means 
of long-lasting  delivery of MEM to the back of the eye.[13] Incorporation of MEM into a 
nanoparticle drug delivery systems could provide a strategy to enhance the efficacy of 
this agent by increasing concentrations in target retinal tissues whilst reducing the risk of 
side-effects associated with systemic dosing regimens.[14] Nanocarriers have also been 
shown to enable loaded drug molecules to penetrate to posterior ocular tissues by 
promoting drug delivery across anterior ocular barriers including the lipidic tear film and 
corneal epithelial barrier and increasing drug residency time after eye drop instillation.[15–
17] Poly(lactic-co-glycolic acid) or PLGA is presently the most widely used biocompatible 
and biodegradable polymer in the field of nanocarrier systems. It is FDA approved and is 
reported safe for the delivery of ophthalmic agents.[18] Moreover, polymeric PLGA 
nanoparticles (NPs) have been reported to facilitate the sustained delivery of other 
existing IOP-lowering agents to intraocular tissues.[17] Previously, PLGA has been 
covalently attached to hydrophilic polymers such as polyethylene glycol (PEG) due to its 
hydrophilicity and biocompatibility. This was found to enhance nanoparticle 
mucoadhesion by increasing residency time on the ocular surface.[19] 
 
In this study, we sought to develop a novel biodegradable PLGA-PEG nanoparticle 
formulation of MEM which could be applied as an eye-drop once a day. Topical 
administration is favored over subtenon or intravitreal implants owing to non-
invasiveness, reduced risk of side-effects, ability to self-administer and inherent 
socioeconomic costs.[13,20] Encapsulation of MEM in MEM-PLGA-PEG NPs was 
achieved using a double emulsion method. Stability, in vitro and ex vivo release of the 
constructed nanosystems were determined prior to assessing the neuroprotective activity 
of optimized formulations in a well-established rodent model of ocular hypertension. 
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2. Results  
2.1 Preparation of a homogeneous nanoparticle suspension of PLGA-PEG-
memantine using the double emulsion method  
MEM-NP were developed using a double emulsion method using ethyl acetate as the 
organic solvent due to its partial water solubility and reduced toxicity compared to 
dichloromethane (class III and II, respectively according to ICH specifications).[21] 
Design of experiments (DoE) was used to obtain a suitable formulation for eye delivery 
studying the modifications of pH and composition of the two aqueous phases (w1 and w2). 
As shown in Figure 1A, smaller MEM-NP average size (Zav) were obtained as the pH of 
the w1 phase was similar to drug pKa (10.7). A reduction in polydispersity index (PI) was 
also observed by maintaining w1 under alkaline conditions thus favouring MEM-NP 
homogeneity (Figure 1B). Encapsulation efficiency (EE) was also found to be maximal 
(80.6 %) at w1 pH 11 and w2 pH 6.5 (Figure 1C). EE values ~80 % were obtained with a 
4.5 pH difference between the two phases, meaning the nanoparticles incorporated 4 
mg/mL of memantine and this formulation was used in subsequent experiments (F6, 
Table 1). 
Optimized MEM-NP were found to have a mean diameter < 200 nm after centrifugation, 
a PI suggesting formulation homogeneity (0.078 ± 0.018), characteristic of the 
monodisperse systems (PI < 0.1) and a sufficiently negative zeta potential (ZP) to suggest 
the NP dispersion may be stable in solution (-26.5 mV, the negative charge increased after 
centrifugation due to PVA removal). Using dynamic light scattering,[22]  particles were 
found to be monodisperse, with a mean diameter of 141.8 nm, (Suppl. Figure 1A&B). 
Results were supported by transmission electron microscopy (TEM) observations, the 
structure of MEM NPs was distinct from the structure of crystalline memantine (Figure 
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2A & B). MEM-NP were found to be spherical and well dispersed with a mean diameter 
of 78.51 nm ± 11.01 nm (supplementary material Figure 3C). AFM results supported this 
observation with smooth spherical NPs with a mean horizontal and vertical distance of 
89.8 nm and 98.08 nm respectively (Figure 2C &D). Differential scanning calorimetry 
(DSC) thermograms are shown in Figure 3A & B. The exotermic peak observed during 
the cooling process of the sample correspond to MEM NP freezing temperature. The 
freezing onset is -15.99 oC and after freezing and heated MEM NP showed a glass 
transition temperature (Tg) endotermic peak at 9.69 
oC. Furthermore, MEM NP and empty 
NP were compared without the cooling process.  The thermograms of MEM NP showed 
that the Tg (56.39 
oC) is slightly increased compared with empty NP (52.85 oC). The 
proton nuclear magnetic resonance (1H-NMR) profile of MEM-NPs, empty nanoparticles 
and empty nanoparticles spiked with memantine are shown in Figure 3C. Here, D2O was 
used as a solvent, with a reference peak (δ=0) from the methyl signal of trimethylsilyl 
propanoic acid (TMSP).[23] Compared to MEM-NP, or empty nanoparticles characteristic 
memantine peaks were observed in MEM-NP spectra (2.2, 1.4 and 0.9 ppm).[24] The 
profile of empty nanoparticles is comparable to that previously reported in the literature, 
with characteristic peaks around 4 ppm and 1.7 ppm corresponding to the CH of lactic 
acid and methylene groups of the glycol and methyl groups of the lactic acid respectively. 
[25,26]As is shown in Figure 3B, one of the striking features is a large peak at 3.7 ppm due 
to the methylene groups of the MePEG.[22,23] Traces of ethyl acetate were observed in the 
sample, with peaks at 4.1 ppm and 1.24 corresponding to the ethyl quadruplet and methyl 
triplet of CH2CH3 respectively, however these were insufficient to cause ocular 
irritation.
[23]  
2.2 PLGA-PEG nanocarriers encapsulate memantine and demonstrate an element 
of sustained release  
  
 
7 
 
The backscattering profile for MEM-NPs maintained at 25 oC for 24 h is shown in Figure 
4. Except for peripheral peaks at the vial edges, a constant signal around 38% could be 
observed throughout the study without variations higher than 10% thus indicating good 
short-term stability of the formulation.[28] In vitro release of memantine fit well (R2 = 
0.976) to a single phase exponential association equation (eq. 1) liberating all memantine 
within 4h with a half-life of 0.74 h (Figure 5). To assess the proportion of memantine that 
had been incorporated into the aqueous interior of the double emulsion compared to the 
surrounding hydrophobic (oil phase) milieu in vitro release from MEM-NPs was fit to a 
one- (eq. 1) or two-phase exponential association equation (eq. 1 and 2 respectively[29]) 
constraining the fast half-life as that for free memantine.  
                                        Y=Y0 + (P-Y0)*(1-exp(-K*x))       (1) 
SF =(P-Y0)*F *.01 
Ss =(P-Y0)*(100-F)*.01 
Y=Y0+ SF *(1-exp(-KF*X)) + SS*(1-exp(-KS*X))     (2) 
where Y0 and P are the starting and final values of % memantine release (fixed as 0% and 
100% respectively) and K is the rate constant in units reciprocal of the y axis. In equation 
2, SF and Ss describe the span of the fast and slow component respectively, KF and KS 
describe the rate of the fast and slow component respectively and F describes the 
percentage of signal due to the fast phase. 
The best fitting model was determined to be eq. 2 using an extra sum of squares F-test (F 
= 45.41, p < 0.0001), with a slow half-life of 6.0 h (R2 = 0.9828). This result suggests a 
portion of the memantine contained within MEM-NPs has been successfully incorporated 
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into the aqueous interior of the double emulsion. Using (eq.2) the proportion of 
memantine in this slow release fraction was estimated to be 8.68% which equates to ~ 
0.35 mg/mL of the total incorporated memantine. As free memantine in solution was 
removed from MEM-NPs prior to conducting this assay, the fast release fraction is likely 
to be memantine rapidly liberated from the nanoparticle oil phase. This may explain why 
the greatest encapsulation of memantine was achieved at the pK of this drug where it has 
no overall charge and at its most lipophilic. 
Ex vivo corneal and scleral permeation studies 
Ex vivo corneal and scleral permeation studies were carried out up to 6 h (Figure 5B & 
C). MEM-NP depicted a slower drug release on scleral tissue than on the cornea. The 
slope for corneal permeation was 6.64 ± 0.17 µg·cm2·h-1 whereas the slope for scleral 
permeation was 0.23 ± 0.01 µg·cm2·h-1. Lag time (TL) was almost null in both tissues,  
suggesting that MEM-NPs achieve the steady-state in the ocular tissue within a few 
minutes after its application.[30] The permeability coefficient (Kp) was 0.01 cm/h for 
cornea and 2.79·10-4 cm/h for scleral. On both cases, the parameter was highly influenced 
by P2 (Kp = P1·P2). P2 corresponds to the partition coefficient inside both tissues although, 
as demonstrated in previous publications, PLGA-PEG NP show significant corneal 
tropism, with a suggestion that memantine could be released slowly from within the 
cornea.[31] In addition, free drug retention in corneal tissue was 0.01 μg/mg whereas in 
sclera it was 10 fold higher (0.11 μg/mg). 
2.3 In vitro cytotoxicity and in vivo ocular tolerance assessment 
In order to assess the safety of the produced MEM-NP, cell viability studies were carried 
out using retinoblastoma (Y-79) and keratinocytes (HaCaT) cells. As can be observed in 
Figure 6A, MEM-NP at 24 or 48 h of exposure did not cause a reduction in cell viability, 
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whereas free memantine was found to be cytotoxic at 50 μM after 48 h (p<0.001) but not 
24 h of cell contact. The free drug also showed toxicity in retinoblastoma cells after short-
term exposure (Figure 6B). These differences in exposure time and toxicity in different 
cell lines might be due to differences in cell metabolism. In contrast to the free drug, 
MEM-NP did not show toxicity in any of the assessed concentrations, with cell viability 
values greater than 80 %, possibly related to the polymeric matrix slowing memantine 
release and reducing cell exposure to cytotoxic concentrations.  
In vitro ocular tolerance was assessed using the Hen’s egg test chorioallantoic membrane 
(HET-CAM).[32] Addition of 0.9 % saline solution to healthy membranes was used as a 
negative control which produced no adverse effects after five minutes. In contrast, 
application of a severe irritant (1 M sodium hydroxide) induced immediate and severe 
haemorrhages, which served as a positive control (Figure 7A). The application of 0.3 mL 
of free memantine onto the chorioallantoic membrane, induced small haemorrhages 
(Figure 7B) suggestive of mild irritation. In contrast instillation of the same volume and 
concentration of MEM-NPs was found to be well-tolerated and induced no detectable 
irritation (Figure 7C & D).[33] Upon completion of these in vitro tests, a tolerance assay 
was conducted in male albino rabbits. Similar to the in vitro result, MEM-NP had a low 
OII and were therefore classified as non-irritant, whereas administration of free 
memantine was found to induce a degree of inflammation, and was therefore classified 
as slightly irritant. 
2.4 MEM-NPs are neuroprotective in a rodent model of ocular hypertension 
After unilateral induction of the Morrison’s ocular hypertension model in Dark Agouti 
(DA) rats, two drops of MEM-NP were administered daily for three weeks. Peak IOP was 
observed 1 day after surgery, and IOP elevation was sustained for at least 7 days (Figure 
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8A). The IOP profile was comparable between MEM-NP and OHT control groups (20.59 
± 3.81 mmHg and 19.81 ± 0.93 mmHg respectively) suggesting that MEM-NP therapy 
did not affect IOP. 
Surviving RGC were visualised histologically in retinal flat mounts using the RGC 
specific nuclear-localized transcription factor Brn3a (Figure 8B). Quantification of RGC 
populations was completed using an automated script as previously described.[34] Global 
RGC density was significantly diminished in the untreated OHT group versus naïve 
controls (p < 0.001, Figure 8A). Treatment with MEM-NP was found to significantly 
protect against OHT induced RGC injury in this model (p < 0.001), suggesting it was 
neuroprotective in a non-IOP-dependent manner. 
3. Discussion 
In the present work, we developed a novel MEM-NP formulation using DoE in 
conjunction with a double emulsion method. MEM-NPs were found to be homogeneous 
with an average diameter < 200 nm (141.8 nm) with high drug loading (4 mg/mL). 
Incorporated memantine was found to be localised at the particle surface and interior 
using in vitro release assays. As a single parameter cannot be used to adequately describe 
the sample distribution,[35] sub 200 nm particle size and spherical shape was confirmed 
using DLS, TEM and AFM investigations, suggesting this formulation would be unlikely 
to cause ocular irritation.[36]  MEM NP were found to be well tolerated using a number of 
established in vitro and in vivo assays and these results suggest that topical MEM-NP is 
safe and well-tolerated formulation with neuroprotective activity in a well-established 
experimental model of glaucoma. 
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The MEM-NP formulation comprised a PLGA-PEG polymeric matrix which was 
synthesized using a modified double emulsion method. This technique was used due to 
its suitability for the encapsulation of hydrophilic compounds, minimising the escape of 
these molecules from the aqueous core so increasing formulation stability, one of the main 
drawbacks of hydrophilic drug loading into liposomes.[21] The greatest memantine 
encapsulation efficiency was observed using pH values of w1 similar to memantine pKa 
(10.7, ChemAxon). A possible explanation for this observation is that memantine is most 
hydrophobic at its pK, maximizing solubility in the nanoparticle oil phase. This 
suggestion is supported by subsequent in vitro release assays which estimate that of the 4 
mg/mL memantine incorporated into the formulation, 0.35 mg/mL was released slowly 
from nanoparticles (suggestive of encapsulation within the aqueous interior), while 3.65 
mg/mL was released at a similar rate to free memantine. As unencapsulated memantine 
was removed from the formulation prior to in vitro assessment, we propose that the more 
rapidly released fraction was instead liberated from the lipophilic nanoparticle 
component. As a result, while 4 mg/mL of drug was incorporated into the formulation, 
0.35 mg/mL of this material was incorporated within the aqueous nanoparticle core (the 
slower release fraction) and this may be the more relevant value to compare with other 
formulations. After confirming the release profile of the MEM-NPs, sclera and cornea of 
rabbits were used to investigate the permeation of formulated memantine across 
intraocular barriers. MEM-NP corneal penetration was found to be higher than scleral 
permeation but, interestingly, the amount of memantine found within scleral tissue could 
suggest that administration of MEM-NPs results in the formation of a drug reservoir in 
the sclera from which memantine diffuses into intraocular tissues. 
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DSC results supported encapsulation of MEM as a result of the increase in Tg observed 
on drug entrapment. The increasing of the Tg of the polymer could be attributed to the 
incorporation of an alkaline drug, which causes interactions between the carboxylic 
groups of the polymer. In addition, results suggest that this formulation will be amenable 
to freeze-dried.[37] In vitro cell viability studies were performed demonstrating that MEM-
NPs were better tolerated than free memantine by epithelial and neuronal cultures. Results 
from HET-CAM irritation tests were in agreement with in vitro observations, confirming 
not only the sensitivity of the in vitro test but also the non-irritant properties of the 
developed formulation and suitability for ocular administration.[29,32] These results are in 
accordance with those obtained by other groups working with PLGA-NPs for ocular 
applications.[33,34] We anticipate that encapsulation of memantine within the NP aqueous 
interior acts to slow memantine release and therefore reduces cell exposure to potentially 
cytotoxic concentrations of this agent. 
Having established the tolerability of MEM-NPs, the neuroprotective effect of this 
formulation on RGC health was next assessed using an established in vivo rodent model 
of ocular hypertension. Quantitative assessment of RGC loss after three weeks of ocular 
hypertension induction was assessed using Brn3a immunofluorescence in conjunction 
with a previously described automatic image segmentation script.[34] Brn3a is a nuclear-
restricted POU-domain family transcription factor expressed exclusively by RGCs (97% 
of the total RGC population) in the rat retina which plays a role in differentiation, survival 
and axonal elongation during development, thus providing an indirect indication of the 
functional state of the RGC.[41] As such, Brn3a several authors have previously used this 
marker to quantify RGC density in several rodent and mammalian glaucoma models.[41,42] 
Twice-daily topical administration of MEM-NPs for three weeks was found to 
significantly protect RGC soma from injury in this model in an IOP independent manner, 
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suggestive of a neuroprotective effect. Although several animal models of glaucoma have 
been described, it is important to remember that they are imperfect and do not presently 
recreate all aspects of the human condition.[35,36] Despite this limitation, models such as 
the Morrison’s ocular hypertension model used in this paper reproduce some aspects of 
the glaucoma, namely RGC loss in response to IOP elevation as  the extent of IOP 
correlates with RGC loss and damage of RGC axons in untreated OHT eyes.[46]  
RGC loss in the rodent model of ocular hypertension is reported to occur via a 
combination of primary and secondary degenerative processes.[34] Where, primary 
degeneration of RGCs occurs as a result of injury and secondary degeneration describes 
the loss of RGCs as a consequence of the primary insult, for example as a result of 
oxidative stress, inflammation or excitotoxicity.[47] Glutamate excitotoxicity has 
previously been reported to play a role in RGC loss in the OHT model.[48] An attractive 
explanation for the neuroprotective effect of topically administered memantine 
nanoparticles in the OHT model could therefore be due to the well documented NMDA 
receptor antagonism of this agent.[49]  
 
In addition to its effect on glutamate excitotoxicity, there are more recent reports that 
memantine can also lower amyloid beta peptide levels in vitro and in a transgenic murine 
model of AD.[50–52] Recent work by Ito et al suggests that the mechanism of memantine 
mediated reduction in amyloid beta is independent of α,β or γ-secretase activity and 
instead influences amyloid precursor protein (APP) trafficking. Here, reduction of APP 
endocytosis results in the accumulation of a greater proportion of cellular APP at the 
plasma membrane where it is predominantly processed via the non-amyloidogenic 
pathway so reducing amyloid beta production.[52] This is significant as there is growing 
evidence for the involvement of amyloid beta accumulation in glaucoma pathology[53–55] 
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and increasing recognition of mechanistic similarities between these neurodegenerative 
disorders.[50,51] In further support of this hypothesis, we recently demonstrated 
brimonidine-mediated RGC neuroprotection (an α2-adrenergic receptor agonist) in the 
OHT model were mediated in part by a reduction in amyloid beta production and 
promotion of the non-amyloidogenic pathway.[55] Finally, as multiple studies now also 
link the progression of age-related macular degeneration (AMD) with amyloid beta 
accumulation,[58] non-amyloidogenic promoting therapies such as brimonidine and 
memantine may also provide useful therapies for the treatment of AMD. 
 
Orally administered memantine has previously been tested in a Phase III clinical trial the 
treatment of primary open-angle glaucoma, however, the trial was reported to have failed 
to meet its primary endpoints.[11]  To date, several hypotheses have been proposed to 
explain the reasons for its failure, including; study endpoints that lacked sufficient power 
to identify a smaller but therapeutically relevant effect and insufficient treatment 
periods.[11] Owing to these study limitations and despite a high-profile failure, the use of 
non-competitive NMDA antagonists for the treatment of glaucoma remains a promising 
therapeutic avenue for the development of novel glaucoma therapies.[59]  
 
While some authors postulate that the use of more potent NMDA receptor antagonists 
such as bis(7)-tacrine may overcome the perceived limitations associated with the use of 
memantine for the treatment of glaucoma,[11] we postulate that by instead developing 
approaches to increase the concentration of memantine delivered to intraocular tissues 
via its incorporation into nanoparticles for local administration could provide an 
alternative strategy to achieve this goal.   
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To date, the majority of the preclinical studies examining memantine for the treatment of 
glaucoma, intraperitoneal,[54,55] subcutaneous,[62] or oral [63] administration routes were 
investigated. For studies involving oral administration in monkeys, doses of between 2 
and 8 mg/kg·day are reported,[64] while Alzheimer’s disease patients are currently 
prescribed between 10 and 20 mg/day. The local administration of memantine permitted 
by our nanoparticle formulation resulted in localised dosing of approximately 0.125 
mg/rat/day. This reduced dosing in combination with localised administration would 
likely reduce the risk of systemic adverse effects associated with memantine therapy[65] 
while ensuring the delivery of therapeutically relevant concentrations of the drug to target 
tissues.  
 
In this study, we demonstrated a novel PLGA-PEG nanocarrier for the delivery of 
therapeutically relevant concentrations to posterior ocular tissues using a rodent model of 
ocular hypertension. The biodegradable and mucoadhesive properties of PLGA-PEG 
nanoparticles are well-documented and likely promoted memantine delivery to 
intraocular tissues through increasing pre-corneal drug residence.[19] Other groups have 
previously formulated memantine into nanoparticles. Prieto and colleagues developed 
Gantrez, a memantine-loaded poly(anhydride) nanoparticle formulation which possessed 
a similar diameter as our formulation but only contained 0.055 mg of memantine per mg 
of nanoparticles.[13] While the authors demonstrated sustained release of memantine from 
these formulations after sub-tenon and intravitreal injection in the rabbit, the authors did 
not investigate topical administration. While these results are of interest, invasive 
intraocular therapeutic administration is less desirable than non-invasive topical 
administration route.[66] More recently, lipoyl–memantine loaded solid lipid 
nanoparticles[67] and memantine-pamonic acid nanocrystalline salts[68] have been 
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described. Each of these formulations exhibited a sub-200 nm size and good homogeneity 
but only solubilized ~0.1 mg/mL of lipoyl–memantine and 0.028 mg/mL of memantine-
pamonic acid respectively. To the authors’ knowledge, neither of these formulations have 
been assessed as a glaucoma therapy.  
 
4. Conclusion 
This study describes a novel PLGA-PEG nanoparticle formulation that that incorporates 
4 mg/mL of memantine with an 80% encapsulation efficiency of which 0.35 mg/mL was 
contained within the particles within the nanoparticle aqueous interior . This formulation 
was found to be better-tolerated than free-memantine by epithelial and neuronal cell 
cultures in vitro and was found to be neuroprotective through significant preservation of 
RGC density in a well-established rodent ocular hypertension model of glaucoma after 
twice-daily topical in vivo. In summary, we propose topical administration of memantine 
loaded nanoparticles as a novel technique as a safe, non-invasive and effective strategy 
for the treatment of glaucoma.  
 
5. Experimental section 
MEM-NP preparation. MEM-NP were prepared by a modification of the double 
emulsion solvent evaporation technique.[69] Briefly, 100 mg of PLGA-PEG was 
dissolved in 2 ml of ethyl acetate. 25 mg of memantine was dissolved into 1 ml of water 
at pH 11. Primary emulsion (w1/o) was obtained by applying ultrasound energy with an 
ultrasonic probe for 30s (38% of amplitude). 2 ml of PVA at 23 mg/mL was added and 
ultrasound was applied for 3 minutes. Finally, 2 ml of PVA 0.3 % was added dropwise 
under magnetic stirring and the w1/o/w2 emulsion was stirred overnight to evaporate the 
organic solvent.  
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Characterization of MEM-NP. MEM-NP Zav and PI were determined by photon 
correlation spectroscopy (PCS) with a Zetasizer Nano ZS (Malvern Instruments, Malvern, 
UK) at 25oC.[39] ZP was evaluated by laser-doppler electrophoresis with M3 PALS system. 
In all the determinations, the samples were diluted with MilliQ water (1:10). Results 
represent mean ± SD, N ≥ 3.  
EE was determined indirectly using a Triple Quadrupole LC/MS/MS Mass Spectrometer 
(Perkin-Elmer Sciex Instruments). Prior to analysis, free drug was separated from 
nanoparticles by filtration using an Ultra 0.5 centrifugal filter device (Amicon Millipore 
Corporation, Ireland). EE was calculated using equation (3); 
EE (%) = 
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑀𝐸𝑀−𝐹𝑟𝑒𝑒 𝑀𝐸𝑀
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑀𝐸𝑀
    (3) 
Memantine quantification was performed in multiple reaction monitoring (MRM) mode 
of an ion-trap MS equipped with an atmospheric pressure electrospray ionization ion 
source and an Agilent 1100 series HPLC system (Agilent Technologies, USA) coupled 
with a Brucker Ion Trap SL (Brucker Daltonics GmbH, Germany). memantine was 
separated on a reversed phase column (Kinetex de 2.6 μm 50 x 2.1 (Phenomenex) using 
methanol 0.1% formic acid in water 55:45 (v/v) as mobile phase. The flow rate was 1 
ml/min at 45 ºC.[70] 
 
Preparation of MEM-NP using a DoE approach. MEM-NP formulation was optimized 
by investigating the influence of pH on NP size, dispersity, ZP and EE (Table 1). The 
effect of a factor (Ex) was calculated according to equation (4): 
    Ex =  
∑ (+)𝑥 −∑ (−)𝑥
𝑛/2
    (4) 
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Where Σx(+) corresponds to the sum of the factors at their highest level (+1) and Σx(-) to 
the sum of the factors at their lowest level and n/2 for the half of the number of 
measurements. In addition, interaction between factors was also elucidated by calculating 
the effect of the first factor at the lowest level of the second factor and subtracting it from 
the effect of the first factor at the highest level of the second factor. 
Morphology studies. MEM-NP were observed by transmission electron microscopy 
(TEM) on a Jeol 1010. To visualize the NP, copper grids were activated with UV light 
and samples were placed on the grid surface. Negative staining was performed with 
uranyl acetate (2% w/v).[28]  
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AFM studies. AFM analysis was performed in a multimode 8 microscopy with Nanoscope 
V electronics (Bruker,  Germany). The microscope mode used was the peak Force tapping 
mode.with an SNL tip (Bruker). The samples were previously diluted (1:10) and about 5 
μl of the solution were dropped to freshly cleaved mica surface and incubated for 5 min. 
Afterwards, the sample was blown off with air. 
 
DSC studies. DSC was performed in an aluminum pan on a DSC-821 (Mettler Toledo) 
under nitrogen atmosphere. 
 
1H NMR studies. 1H-NMR was used to confirm both PLGA-PEG structure on the NP and 
drug incorporation. MEM-NP were centrifuged and dissolved in D2O. The spectrum was 
recorded at 298 K on a Varian Inova 500 MHz spectrometer (Agilent Technologies, Santa 
Clara, CA, USA).[19] 
 
Stability studies. MEM-NP stability was assessed by light backscattering by means of a 
Turbiscan®Lab. For this purpose, a glass measurement cell was filled with 20 ml of 
MEM-NP. The light source, pulsed near infrared light-emitting diode LED (λ=880 nm), 
was received by a backscattering detector at an angle of 45° from the incident beam. 
Readings were carried out every hour for 24 h.[31] 
 
In vitro drug release. In vitro release of memantine from MEM-NPs was evaluated using 
the dialysis bag technique under sink conditions and results compared to free 
memantine.[63,64] The release medium was composed of a PBS buffer solution (PBS 0.1 
M, pH 7.4) and temperature maintained at 32°C (ocular surface temperature) with stirring. 
At predetermined time intervals, 1 ml samples were withdrawn from the reaction mixture 
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and replaced with 1 mL of fresh buffer. The memantine content of each aliquot was 
evaluated using Graphpad Prism v5.0.  
 
Corneal and scleral permeation. Ex vivo corneal and scleral permeation experiments were 
carried out using New Zealand rabbits (male, weighting 2.5–3.0 kg), under veterinary 
supervision. Rabbits were anesthetized with intramuscular administration of ketamine 
HCl (35 mg/kg) and xylazine (5 mg/kg) and euthanized by an overdose of sodium 
pentobarbital (100 mg/kg). The cornea and sclera of the animals were excised and fixed 
between the donor and receptor compartments of Franz diffusion cells (available 
permeation area of 0.64 cm2). The receptor compartment was filled with Bicarbonate 
Ringer’s (BR) solution and kept at 32 and 37 ± 0.5 ºC for corneal and scleral permeation 
respectively. 1 ml of the formulation was placed in the donor compartment and 300 μl 
were withdrawn from the receptor chamber at fixed time points and immediately replaced 
by BR. The cumulative drug amount permeated was calculated at each time point from 
the drug in the receiving medium and plotted as function time.[26,66] All experiments using 
rabbits were performed according to the Ethics Committee of Animal Experimentation at 
the University of Barcelona. The amount of memantine retained in the tissues was also 
determined by extracting the drug from the tissue with methanol: water (75:25, v/v) under 
sonication for 30 minutes.[30] 
 
Cytotoxicity assay. Human retinoblastoma cells (Y-79) and adherent human keratinocyte 
cells (HaCaT[73]) were purchased from Cell Lines Services (CLS, Eppelheim, Germany) 
and were maintained in RPMI-1640 and DMEM media respectively. Cell viability was 
assayed with Alamar Blue (Alfagene, Invitrogene, Portugal) at 24 and 48 h as was 
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previously described.[27,68] Data was analyzed by calculating cell viability through the 
percentage of Alamar blue reduction compared to the control (untreated cells).[75,76] 
Ocular tolerance test: HET-CAM and Draize irritation test. In order to evaluate the risk 
of ocular irritation caused by free memantine and MEM-NP administered as eye drops, 
ocular tolerance tests in vivo and in vitro were conducted. Ocular tolerance was assessed 
in vitro using the HETCAM® test (Figure 4 of supplementary material).[31] Scores of 
irritation potential were grouped into four categories.[31] Subsequent in vivo ocular 
tolerance assays were performed using primary eye irritation test of Draize et. al (1994) 
with New Zealand rabbits (male, 2.5 kg) (n=3/group).[33] The formulation was instilled in 
the conjunctival sac of the right eye and a gentle massage was applied. The appearance 
of irritation was observed at the time of administration and after 1 hour, using the left eye 
as a negative control. The OII was calculated by direct observation of the anterior segment 
of the eye, noting the possible injury of the conjunctiva, iris and cornea. [33] 
In vivo studies: therapeutic efficacy. Induced glaucoma experimental models such as 
Morrison model of ocular hypertension were previously validated by our group.[48] Adult 
male DA rats weighing 150 to 200 g were treated with procedures approved by the U.K. 
Home Office and in compliance with the ARVO Statement for the Use of Animals in 
Ophthalmic and Vision Research. For the present study 10 rats were used as control 
without glaucoma induction, and 20 rats underwent surgery to elevate intraocular pressure 
(IOP) by injection of hypertonic saline solution (1.80 M) into two episcleral veins. The 
rats undergoing chronic ocular hypertension were divided in two groups (10 rats/group): 
control group (treated with saline serum) and MEM-NPs group (treated with two drops 
of MEM-NPs/day). Contralateral unoperated eyes were also used as a control. The IOP 
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of both eyes was measured weekly using a Tonopen XL (Medtronic Solan, Jacksonville, 
FL). 
 
Histology and RGC quantification. Animals were sacrificed three weeks after OHT 
induction. Eyes were enucleated and fixed in 4% fresh paraformaldehyde overnight. 
Whole-mount retinas were stained for the RGC specific nuclear-localized transcription 
factor Brn3a using a MAB1585 antibody (1:350; Merck Millipore). Immunoreactivity 
was detected with AlexaFluor®555 donkey anti-mouse (1:200; Merck Millipore, 
Darmstadt, Germany). Retinas were mounted and examined under confocal microscopy 
(LSM 710; Carl Zeiss Micro Imaging GmbH, Jena, Germany) as a tiled z-stack at 10x 
magnification generating a single plane maximum projection of the RGC layers for 
subsequent analysis. Image acquisition settings were kept constant for all retinas imaged, 
allowing comparison of Brn3a expression in each experimental group.[34]  Automatic 
quantification of Brn3a-labelled RGC was achieved using an algorithm previously 
validated. [34,77] Naïve and OHT only Brn-3a whole retinal counts from DA rats was 
obtained from our previous work [34]. 
 
Statistical analysis. Statistical evaluation of data was performed using one-way analysis 
of variance (ANOVA) with Tukey multiple comparison post-hoc test to assess differences 
between groups and p < 0.05 was considered significant. 
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Table 1. Characteristics of memantine loaded nanoparticles. Design of experiments 
matrix and results according to central factorial design to study pH influence of the inner 
and external water phases (MEM-NP prepared with 20mg/mL PLGA-PEG and 5mg/mL 
of MEM) 
 pH w1 pH w2 Zav (nm) PI ZP (mV) EE (%) 
Factorial points 
F1 12.0 +1 3.5 -1 234.0 ± 0.6 0.09 ± 0.02 -5.67 ± 0.28 78.45 
F2 12.0 +1 6.5 +1 225.4 ± 1.2 0.04 ± 0.02 -5.65 ± 0.12 79.60 
F3 12.0 +1 5.0 0 197.9 ± 3.64 0.03 ± 0.02 -5.17 ± 0.06 79.43 
F4 10.0 -1 6.5 +1 221.3 ± 4.01 0.18 ± 0.02 -5.19 ± 0.16 80.81 
F5 10.0 -1 3.5 -1 268.3 ± 4.83 0.21 ± 0.02 -5.87 ± 0.19 79.03 
F6 11.0 0 6.5 +1 193.1 ± 0.42 0.05 ± 0.01 -4.41 ± 0.15 80.64 
F7 11.0 0 3.5 -1 196.1 ± 3.33 0.04 ± 0.01 -4.39 ± 0.26 78.40 
F8 10.0 -1 5.0 0 198.7 ± 3.03 0.12 ± 0.01 -4.82 ± 0.61 77.86 
Center points 
F9 11.0 0 5.0 0 217.9 ± 1.5 0.11 ± 0.02 -5.03 ± 0.33 80.34 
F10 11.0 0 5.0 0 219.5 ± 2.4 0.14 ± 0.01 -5.08 ± 0.24 79.99 
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Figure 1. Characteristics of memantine loaded nanoparticles in response to changes in pH 
of w1 and w2 phases. Results from DoE experiments regarding the influence of pH on double 
emulsion solvent evaporation method. The effect of pH on mean MEM-NP [A] diameter, [B] 
polydispersity (PI) and [C] Encapsulation Efficiency (EE) was investigated. 
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Figure 2. Transmission electron microscopy and Atomic force microscopy of MEM NP. 
[A] Micrograph confirming the crystalline structure of free memantine, [B] TEM micrograph 
illustrating the spherical structure of memantine loaded nanoparticles (MEM-NP), scale bar of 
B.1) corresponding to 500 nm and B.2) 1 μm. [C] 2D AFM microsgraph MEM NP, [D] 3D 
analysis corresponding to the 2D micrographs. 
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Figure 3. [A] DSC curves starting at 25 oC (freezing until -80 oC and heating until 25 oC at 10 
oC/min) and [B] DSC curves of MEM NP and empty NP starting at 25 oC and heating until 300 
oC (heating rate 10 oC/min) [C] 1 H-NMR spectra of nanoparticles spiked with memantine, 
memantine loaded nanoparticles and empty nanoparticles. 
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Figure 4. Backscattering profile of memantine loaded nanoparticles demonstrates the 
formulation remains stable when stored at room temperature for 24 hours. 
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Figure 5. In vitro release of memantine and ex vivo permeation assays. [A] In vitro release 
of free memantine (MEM) versus memantine loaded nanoparticles (MEM-NP) adjusted to the 
best fit kinetic models (single-phase exponential association (eq.1) or two-phase exponential 
association (eq.2) respectively. Ex vivo assessment of the [B] corneal and [C] scleral permeation 
of MEM-NPs. 
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Figure 6.  Memantine loaded nanoparticles are well tolerated by epithelial and neuronal 
cultures in vitro. Cell viability was assessed using the Alamar blue viability assay with the [A] 
keratinocyte cell line and [B] retinoblastoma cells. Values are expressed as mean ± SD. 
Significant differences between free memantine (MEM) and MEM-NP at same exposure time 
and concentration are represented as $p < 0.05, $$p < 0.01 and $$$p < 0.001 and $$$$p < 0.0001. 
Significant differences between the exposure time with same formulation and concentration are 
represented as *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001. 
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Figure 7. Ocular tolerance assessment of memantine and memantine loaded 
nanoparticles. HET-CAM test results 5 minutes after exposure of 0.3 mL of [A] 0.9% sodium 
cloride (negative control), [B] 1M sodium hydroxide (positive control), [C] memantine loaded 
nanoparticles (MEM-NP), [D] free memantine (MEM) memantine loaded nanoparticles 
(MEM-NP). [E] Classification of the ocular irritation potential in vitro and in vivo. 
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Figure 8. Topical administration of memantine loaded nanoparticles protects RGC soma 
against ocular hypertension induced cell loss. [A] IOP profiles of OHT only, OHT + MEM-
NP and OHT contralateral eyes. * p < 0.05, significant differences between OHT and the co-
eye; $p < 0.05, significant differences between OHT and OHT MEM NPs. [B] Comparable 
Brn3a labelled retinal flat mounts from contralateral eyes (top), OHT eyes treated with MEM-
NPs (middle) and OHT only group (bottom). [C] Whole retinal RGC density measurements indicate 
that while OHT induction caused a significant reduction in RGC density, RGC loss was 
mitigated by twice-daily administration of MEM-NPs (one-way ANOVA with Tukey post hoc 
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test, ***p < 0.0001). Values are expressed as mean ± SE. Naïve and OHT only Brn-3a whole 
retinal counts from DA rats was obtained from our previous work [34]. 
 
